Singapore markets open in 1 hour

Iovance Biotherapeutics, Inc. (IOVA)

NasdaqGM - NasdaqGM Real-time price. Currency in USD
Add to watchlist
7.98-0.15 (-1.85%)
At close: 04:00PM EST
7.95 -0.03 (-0.38%)
After hours: 07:01PM EST
Currency in USD

Valuation measures4

Market cap (intra-day) 1.28B
Enterprise value 1.00B
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)3.26
Enterprise value/revenue N/A
Enterprise value/EBITDA -2.70

Trading information

Stock price history

Beta (5Y monthly) 0.12
52-week change 3-51.46%
S&P500 52-week change 3-7.75%
52-week high 318.73
52-week low 35.42
50-day moving average 36.69
200-day moving average 39.97

Share statistics

Avg vol (3-month) 35.12M
Avg vol (10-day) 37.16M
Shares outstanding 5157.84M
Implied shares outstanding 6N/A
Float 8107.73M
% held by insiders 10.52%
% held by institutions 1118.20%
Shares short (12 Jan 2023) 420.12M
Short ratio (12 Jan 2023) 45.53
Short % of float (12 Jan 2023) 413.39%
Short % of shares outstanding (12 Jan 2023) 412.74%
Shares short (prior month 14 Dec 2022) 419.08M

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:100
Last split date 325 Sept 2013

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Sept 2022


Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-35.58%
Return on equity (ttm)-71.41%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -383.47M
Net income avi to common (ttm)-389.9M
Diluted EPS (ttm)-2.30
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)360.17M
Total cash per share (mrq)2.28
Total debt (mrq)80.11M
Total debt/equity (mrq)20.35
Current ratio (mrq)4.67
Book value per share (mrq)2.49

Cash flow statement

Operating cash flow (ttm)-268.94M
Levered free cash flow (ttm)-155.24M